Literature DB >> 20076852

Platelet activation and reactivity in the convalescent phase of ischaemic stroke.

Maria Lukasik1, Marcin Rozalski, Boguslawa Luzak, Slawomir Michalak, Wojciech Kozubski, Cezary Watala.   

Abstract

The study was aimed at the evaluation of blood platelet activation and reactivity in patients in the convalescent phase of stroke (n=58) and controls matched in respect to risk factors of vascular pathology (n=55). Both groups were treated daily with acetylsalicylic acid (ASA), 150 mg/day. Using flow cytometry, the expressions of P-selectin and the active GP IIb/IIIa receptor, as well as the fraction of platelet-derived microparticles (PMPs) and total platelet aggregates (Ag), were evaluated in non-stimulated platelets and in platelets stimulated in vitro by thrombin, thrombin receptor activating peptide (TRAP) or ADP. The expression of P-selectin in non-stimulated platelets was found to be significantly (p=0.04) lower in stroke patients. In parallel, these patients manifested a significantly (p=0.0008) higher proportion of PMPs and a lowered (p=0.003) proportion of Ag, as compared to the controls. In the stroke patients the increased expressions of P-selectin and active GP IIb/IIIa in TRAP- or ADP-activated cells were less pronounced (p<0.01), while the increments in PMP fraction remained higher (p<0.05). Our results may indicate that chronic platelet activation develops in patients in the convalescent phase of stroke and the process of PMP generation prevails over blood platelet degranulation and aggregation. This shift may be particularly unfavourable due to the procoagulative and proatherosclerotic properties of PMPs, accompanied by their decreased sensitivity to the action of antiplatelet drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20076852     DOI: 10.1160/TH09-08-0599

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles.

Authors:  Bence György; Tamás G Szabó; Mária Pásztói; Zsuzsanna Pál; Petra Misják; Borbála Aradi; Valéria László; Eva Pállinger; Erna Pap; Agnes Kittel; György Nagy; András Falus; Edit I Buzás
Journal:  Cell Mol Life Sci       Date:  2011-05-11       Impact factor: 9.261

2.  The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke.

Authors:  Malgorzata Pawelczyk; Henryk Chmielewski; Beata Kaczorowska; Monika Przybyła; Zbigniew Baj
Journal:  Arch Med Sci       Date:  2015-03-14       Impact factor: 3.318

3.  Platelets, gender and acute cerebral infarction.

Authors:  Petter Järemo; Marie Eriksson-Franzen; Micha Milovanovic
Journal:  J Transl Med       Date:  2015-08-16       Impact factor: 5.531

Review 4.  Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse.

Authors:  Lina Badimon; Rosa Suades; Gemma Arderiu; Esther Peña; Gemma Chiva-Blanch; Teresa Padró
Journal:  Front Cardiovasc Med       Date:  2017-12-18

5.  Platelet microparticles: a biomarker for recanalization in rtPA-treated ischemic stroke patients.

Authors:  Andrew Bivard; Lisa F Lincz; Jane Maquire; Mark Parsons; Christopher Levi
Journal:  Ann Clin Transl Neurol       Date:  2017-01-25       Impact factor: 4.511

6.  Initiation and Propagation of Vascular Calcification Is Regulated by a Concert of Platelet- and Smooth Muscle Cell-Derived Extracellular Vesicles.

Authors:  Leon J Schurgers; Asim C Akbulut; Dawid M Kaczor; Maurice Halder; Rory R Koenen; Rafael Kramann
Journal:  Front Cardiovasc Med       Date:  2018-04-06

7.  Circulating Microparticles in Patients with Symptomatic Carotid Disease Are Related to Embolic Plaque Activity and Recent Cerebral Ischaemia.

Authors:  Neghal Kandiyil; Shane T MacSweeney; Stan Heptinstall; Jane May; Susan C Fox; Dorothee P Auer
Journal:  Cerebrovasc Dis Extra       Date:  2019-04-03

8.  Flow Cytometric Investigation of Classical and Alternative Platelet Activation Markers.

Authors:  Béla Nagy; Ildikó Beke Debreceni; János Kappelmayer
Journal:  EJIFCC       Date:  2013-01-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.